Back to results
US 2011/0212117 A1Published application
Influenza hemagglutinin and neuraminidase variants
AssigneeMedImmune, LLC
InventorsChin-Fen Yang, George Kemble
Life of this patent
Estimating the term…
Abstract
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Claims24
1-82. (canceled)
A reassortant influenza virus comprising a genome segment encoding one or more polypeptides comprising the amino acid sequences selected from the group consisting of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28, residues 17-345 of SEQ ID NO:
- 2, residues 346-566 of SEQ ID NO:
- 2, residues 18-343 of SEQ ID NO:
- 6, residues 344-565 of SEQ ID NO:
- 6, residues 18-361 of SEQ ID NO:
- 10, residues 16-361 of SEQ ID NO:
- 10, residues 362-584 of SEQ ID NO:
- 10, residues 17-345 of SEQ ID NO:
- 14, residues 346-566 of SEQ ID NO:
- 14, residues 18-343 of SEQ ID NO:
- 18, residues 344-565 of SEQ ID NO:18, residues 16-362 of SEQ ID NO:
- 22, residues 363-585 of SEQ ID NO:
- 22, residues 16-362 of SEQ ID NO:
- 26 and residues 363-585 of SEQ ID NO:26.
11 more elements
A method for producing reassortant influenza viruses in cell culture, the method comprising:
- i) introducing a plurality of vectors comprising polynucleotides corresponding to an influenza virus genome into a population of host cells capable of supporting replication of influenza virus, which plurality of vectors comprises polynucleotides corresponding to at least 6 internal genome segments of a first influenza strain, and at least one genome segment of a second influenza strain, wherein the at least one genome segment of the second influenza strain comprises a polynucleotide comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28, residues 17-345 of SEQ ID NO:
- 2, residues 346-566 of SEQ ID NO:
- 2, residues 18-343 of SEQ ID NO:
- 6, residues 344-565 of SEQ ID NO:
- 6, residues 18-361 of SEQ ID NO:
- 10, residues 16-361 of SEQ ID NO:
- 10, residues 362-584 of SEQ ID NO:
- 10, residues 17-345 of SEQ ID NO:
- 14, residues 346-566 of SEQ ID NO:
- 14, residues 18-343 of SEQ ID NO:
- 18, residues 344-565 of SEQ ID NO:18, residues 16-362 of SEQ ID NO:
- 22, residues 363-585 of SEQ ID NO:
- 22, residues 16-362 of SEQ ID NO:
- 26 and residues 363-585 of SEQ ID NO:
- 26;
- ii) culturing the population of host cells;
- and
- iii) recovering a plurality of influenza viruses.
16 more elements
A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising:
- administering to the subject, a reassortant virus comprising:
- a) a polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:
- 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27;
- b) a polynucleotide comprising a nucleotide sequence selected from the group consisting of residues 74-1060 of SEQ ID NO:
- 1, residues 1061-1723 of SEQ ID NO:
- 1, residues 81-1058 of SEQ ID NO:
- 5, residues 1059-1724 of SEQ ID NO:
- 5, residues 85-1116 of SEQ ID NO:
- 9, residues 79-1116 of SEQ ID NO:
- 9, residues 1117-1785 of SEQ ID NO:
- 9, residues 78-1064 of SEQ ID NO:
- 13, residues 1065-1727 of SEQ ID NO:
- 13, residues 78-1055 of SEQ ID NO:
- 17, residues 1056-1721 of SEQ ID NO:
- 17, residues 78-1118 of SEQ ID NO:
- 21, residues 1119-1787 of SEQ ID NO:
- 21, residues 75-1115 of SEQ ID NO:
- 25, and residues 1116-1787 of SEQ ID NO:
- 25;
- c) a polynucleotide sequence encoding a polypeptide comprising an amino acid sequence of any one of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28, or a complementary polynucleotide sequence thereof;
- or
- d) a polynucleotide sequence encoding a polypeptide comprising an amino acid sequence of any one of residues 17-345 of SEQ ID NO:
- 2, residues 346-566 of SEQ ID NO:
- 2, residues 18-343 of SEQ ID NO:
- 6, residues 344-565 of SEQ ID NO:
- 6, residues 18-361 of SEQ ID NO:10, residues 16-361 of SEQ ID NO:
- 10, residues 362-584 of SEQ ID NO:
- 10, residues 17-345 of SEQ ID NO:
- 14, residues 346-566 of SEQ ID NO:
- 14, residues 18-343 of SEQ ID NO:18, residues 344-565 of SEQ ID NO:
- 18, residues 16-362 of SEQ ID NO:
- 22, residues 363-585 of SEQ ID NO:
- 22, residues 16-362 of SEQ ID NO:
- 26 and residues 363-585 of SEQ ID NO:
- 26;
- in an amount effective to produce an immunogenic response against the viral infection.
34 more elements
An isolated or recombinant polypeptide, which polypeptide is selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:
- 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27;
- b) a polypeptide comprising an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of residues 74-1060 of SEQ ID NO :
- 1, residues 1061-1723 of SEQ ID NO:
- 1, residues 81-1058 of SEQ ID NO:
- 5, residues 1059-1724 of SEQ ID NO:
- 5, residues 85-1116 of SEQ ID NO:
- 9, residues 79-1116 of SEQ ID NO:
- 9, residues 1117-1785 of SEQ ID NO:
- 9, residues 78-1064 of SEQ ID NO:
- 13, residues 1065-1727 of SEQ ID NO:13, residues 78-1055 of SEQ ID NO:
- 17, residues 1056-1721 of SEQ IDNO:
- 17, residues 78-1118 of SEQ ID NO:
- 21, residues 1119-1787 of SEQ ID NO:
- 21, residues 75-1115 of SEQ ID NO:
- 25, and residues 1116-1787 of SEQ ID NO:
- 25;
- c) a polypeptide comprising an amino acid sequence selected from SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28;
- and
- d) a polypeptide comprising an amino acid sequence selected from residues 17-345 of SEQ ID NO:
- 2, residues 346-566 of SEQ ID NO:
- 2, residues 18-343 of SEQ ID NO:
- 6, residues 344-565 of SEQ ID NO:
- 6, residues 18-361 of SEQ ID NO:
- 10, residues 16-361 of SEQ ID NO:
- 10, residues 362-584 of SEQ ID NO:
- 10, residues 17-345 of SEQ ID NO:
- 14, residues 346-566 of SEQ ID NO:
- 14, residues 18-343 of SEQ ID NO:
- 18, residues 344-565 of SEQ ID NO:18, residues 16-362 of SEQ ID NO:
- 22, residues 363-585 of SEQ ID NO:
- 22, residues 16-362 of SEQ ID NO:
- 26 and residues 363-585 of SEQ ID NO:
- 265
31 more elements
An isolated or recombinant polynucleotide, which polynucleotide is selected from the group consisting of:
- a) a polynucleotide comprising a nucleotide sequence of one of SEQ ID NOS:
- 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27, or a complementary sequence thereof;
- b) a polynucleotide comprising a nucleotide sequence of one of residues 74-1060 of SEQ ID NO:
- 1, residues 1061-1723 of SEQ ID NO:1, residues 81-1058 of SEQ ID NO:
- 5, residues 1059-1724 of SEQ ID NO:
- 5, residues 85-1116 of SEQ ID NO:
- 9, residues 79-1116 of SEQ ID NO:
- 9, residues 1117-1785 of SEQ ID NO:
- 9, residues 78-1064 of SEQ ID NO:
- 13, residues 1065-1727 of SEQ ID NO:
- 13, residues 78-1055 of SEQ ID NO:
- 17, residues 1056-1721 of SEQ ID NO:
- 17, residues 78-1118 of SEQ ID NO:
- 21, residues 1119-1787 of SEQ ID NO:
- 21, residues 75-1115 of SEQ ID NO:
- 25, and residues 1116-1787 of SEQ ID NO:
- 25;
- c) a polynucleotide sequence encoding a polypeptide comprising an amino acid sequence of any one of SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28, or a complementary polynucleotide sequence thereof;
- and
- d) a polynucleotide sequence encoding a polypeptide comprising an amino acid sequence of any one of residues 17-345 of SEQ ID NO:
- 2, residues 346-566 of SEQ ID NO:
- 2, residues 18-343 of SEQ ID NO:
- 6, residues 344-565 of SEQ ID NO:
- 6, residues 18-361 of SEQ ID NO:10, residues 16-361 of SEQ ID NO:
- 10, residues 362-584 of SEQ ID NO:
- 10, residues 17-345 of SEQ ID NO:
- 14, residues 346-566 of SEQ ID NO:
- 14, residues 18-343 of SEQ ID NO:18, residues 344-565 of SEQ ID NO:
- 18, residues 16-362 of SEQ ID NO:22, residues 363-585 of SEQ ID NO:22, residues 16-362 of SEQ ID NO:
- 26 and residues 363-585 of SEQ ID NO:
- 26.
29 more elements
Dependencies are inferred from the claim text.